S. Polyakov

1.6k citations

21 papers · 993 · 2 hit papers · h-index 8

Impact in

Pulmonary and Respiratory Medicine top 2%
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
Cancer Research top 10%
- Cancer, Lipids, and Metabolism

Papers in

Pulmonary and Respiratory Medicine 8
- Prostate Cancer Treatment and Research 7
Surgery 6
- Bladder and Urothelial Cancer Treatments 5

Co-authors: Mindaugas Jievaltas (7 shared papers)Iris Kuss (6 shared papers)Toni Sarapohja (7 shared papers)Teuvo L.J. Tammela (7 shared papers)Neal D. Shore (7 shared papers)Amir Snapir (6 shared papers)Albertas Ulys (7 shared papers)Egils Vjaters (7 shared papers)
Journals: Journal of Clinical Oncology (3 papers)Annals of Oncology (3 papers)New England Journal of Medicine (2 papers)World Journal of Urology (1 paper)International Journal of Gynecological Cancer (1 paper)
Partner nations: Belarus United States Brazil

In The Last Decade

S. Polyakov

18 papers receiving 979 citations

S. Polyakov's Hit Papers

align trajectories log scale

Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide 2020 · 236 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2020 New England Journal of Medicine
2019 New England Journal of Medicine

Peers

Countries citing papers authored by S. Polyakov

Since Specialization

Citations

This map shows the geographic impact of S. Polyakov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Polyakov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Polyakov more than expected).

Fields of papers citing papers by S. Polyakov

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Polyakov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Polyakov. The network helps show where S. Polyakov may publish in the future.

Co-authors

The 25 scholars most cited alongside S. Polyakov, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with S. Polyakov Line = papers co-authored together S. Polyakov links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 21 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer New England Journal of Medicine ·Karim Fizazi, Neal D. Shore, Teuvo L.J. Tammela, Albertas Ulys, Egils Vjaters, S. Polyakov, Mindaugas Jievaltas, Murilo Luz, B. Yа. Alekseev, Iris Kuss, Christian Kappeler, Amir Snapir, Toni Sarapohja, Matthew R. Smith Hit paper breakdown →	2019	613
2	Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide New England Journal of Medicine ·Karim Fizazi, Neal D. Shore, Teuvo L.J. Tammela, Albertas Ulys, Egils Vjaters, S. Polyakov, Mindaugas Jievaltas, Murilo Luz, B. Yа. Alekseev, Iris Kuss, Marie‐Aude Le Berre, Oana Petrenciuc, Amir Snapir, Toni Sarapohja, Matthew Smith Hit paper breakdown →	2020	236
3	Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC). Journal of Clinical Oncology ·Karim Fizazi, Neal D. Shore, Teuvo L.J. Tammela, Albertas Ulys, Egils Vjaters, S. Polyakov, Mindaugas Jievaltas, Murilo Luz, B. Yа. Alekseev, Iris Kuss, Marie‐Aude Le Berre, Oana Petrenciuc, Amir Snapir, Toni Sarapohja, Matthew Smith	2020	34
4	Results of a prospective randomized study assessing the efficacy of fluorescent cystoscopy-assisted transurethral resection and single instillation of doxorubicin in patients with non-muscle-invasive bladder cancer World Journal of Urology ·A.I. Rolevich, A.G. Zhegalik, A.A. Mokhort, (unknown), V. Vasilevich, S. Polyakov, Sergey Krasny, О. Г. Суконко	2016	29
5	Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial European Journal of Cancer ·Matthew R. Smith, Neal D. Shore, Teuvo L.J. Tammela, Albertas Ulys, Egils Vjaters, S. Polyakov, Mindaugas Jievaltas, Murilo Luz, B. Yа. Alekseev, Iris Kuss, Marie‐Aude Le Berre, Ateesha F. Mohamed, Dawn Odom, Jennifer Bartsch, Amir Snapir, Toni Sarapohja, Karim Fizazi	2021	24
6	Surgeon has a major impact on long-term recurrence risk in patients with non-muscle invasive bladder cancer Editor-in-Chief s Voice List of Authors is an Important Element in a Scientific Publication ·A.I. Rolevich, A. Minich, T.I. Nabebina, S. Polyakov, Sergey Krasny, О. Г. Суконко	2016	17
7	Long-term results of a single-center prospective randomized trial assessing efficacy of a shortened course of adjuvant chemotherapy after radical cystectomy in patients with locally advanced bladder cancer Editor-in-Chief s Voice List of Authors is an Important Element in a Scientific Publication ·A.G. Zhegalik, S. Polyakov, A.I. Rolevich, Alexander N Volkov, (unknown), Vladimir Vasilevich, A.A. Mokhort, Sergey Krasny, О. Г. Суконко	2020	9
8	Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial European Urology ·Martin Bögemann, Neal D. Shore, Matthew R. Smith, Teuvo L.J. Tammela, Albertas Ulys, Egils Vjaters, S. Polyakov, Mindaugas Jievaltas, Murilo Luz, B. Yа. Alekseev, Thierry Lebrét, Martin Schostak, Frank Verholen, Marie‐Aude Le Berre, Shankar Srinivasan, Jorge Ortíz, Ateesha F. Mohamed, Toni Sarapohja, Karim Fizazi	2022	8
9	ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). Journal of Clinical Oncology ·Karim Fizazi, Neal D. Shore, Teuvo L.J. Tammela, Albertas Ulys, Egils Vjaters, S. Polyakov, Mindaugas Jievaltas, Murilo Luz, B. Yа. Alekseev, Iris Kuss, Christian Kappeler, Amir Snapir, Toni Sarapohja, Matthew R. Smith	2019	6
10	Clinical efficacy of plasmid encoding p62/SQSTM1 (Elenagen) in combination with gemcitabine in patients with platinum-resistant ovarian cancer: a randomized controlled trial Frontiers in Oncology ·S. А. Krasny, Y. Baranau, S. Polyakov, Ekaterina Zharkova, Olga Streltsova, Aliona Filimonava, Volha Siarheyeva, Sviatlana Kazlouskaya, Anton Khorau, Vladimir L. Gabai, Alexander Shneider	2024	3
11	Efficacy of fluorescent cystoscopy-assisted transurethral resection in patients with non-muscle invasive bladder cancer and quality of surgery: post-hoc analysis of а prospective randomized study Editor-in-Chief s Voice List of Authors is an Important Element in a Scientific Publication ·A.I. Rolevich, A. Minich, Vladimir Vasilevich, A.G. Zhegalik, A.A. Mokhort, T.I. Nabebina, Sergey Krasny, S. Polyakov, О. Г. Суконко	2019	3
12	759P Adding dosing of plasmid encoding p62/SQSTM1 to gemcitabine chemotherapy may provide clinical benefits to patients with platinum-resistant ovarian cancer Annals of Oncology ·S. Polyakov, S. А. Krasny, Edvard Zhavrid, Y. Baranau, Olga Sergeeva, K. Zharkova, Anton Khorau, S. N. Kozlovskaya, Vladimir L. Gabai, Alexander Shneider	2021	2
13	223P Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC) Annals of Oncology ·Karim Fizazi, Neal D. Shore, Teuvo L.J. Tammela, Albertas Ulys, Egils Vjaters, S. Polyakov, Mindaugas Jievaltas, Murilo Luz, B. Yа. Alekseev, Iris Kuss, M-A. Le Berre, Oana Petrenciuc, Amir Snapir, Toni Sarapohja, Matthew Smith	2020	2
14	278P Plasmid encoding p62/SQSTM1 administered in combination with CMF chemotherapy improves outcomes in metastatic triple-negative breast cancer patients Annals of Oncology ·S. А. Krasny, S. Polyakov, Edvard Zhavrid, Anton Khorau, Y. Baranau, S. N. Kozlovskaya, Olga Sergeeva, K. Zharkova, Albert Sufianov, Vladimir L. Gabai, Alexander Shneider	2021	2
15	Simultaneous or staged surgery in patients with kidney tumors and concomitant cardiac disease Editor-in-Chief s Voice List of Authors is an Important Element in a Scientific Publication ·Uladzimir Andrushchuk, Yury Ostrovsky, Sergey Krasny, S. Polyakov, V. Zharkov, A.I. Rolevich, С А Курганович, Valery Krutau, Siarhei Amelchanka	2017	2
16	Pelvic Exenteration in Patients with Persistent and Recurrent Cervical Cancer: A Case Series from Belarus Olga P Matylevich, Kathleen M. Schmeler, S. Polyakov, S Mavrichev, И А Косенко, S. А. Krasny	2021	1
17	Effects of the baseline prognostic factors on efficacy of the p62/SQSTM1-encoding plasmid combined with gemcitabine in patients with recurrent platinum-resistant ovarian cancer. Journal of Clinical Oncology ·Alexander Shneider, S. Polyakov, Y. Baranau, Vlad Gabai, Ekaterina Zharkova, Olga Streltsova, Aliona Filimonava, Volha Siarheyeva, Sviatlana Kazlouskaya, Anton Khorau, Bhavana Pothuri, S. А. Krasny	2023	1
18	Long-term benefit of fluorescent cystoscopy-assisted transurethral resection in patients with non-muscle invasive bladder cancer is dependent on quality of surgery European Urology Supplements ·A.I. Rolevich, A. Minich, A.G. Zhegalik, A.A. Mokhort, V. Vasilevich, T.I. Nabebina, S. А. Krasny, S. Polyakov	2017	1
19	Efficacy of P62-expressing plasmid in treatment of canine osteoarthritis pain: a pilot study Frontiers in Veterinary Science ·Vladimir L. Gabai, Evgeny A. Bakin, Maxim Harold Langs, Robert Devlin, S. А. Krasny, Yauheni Baranou, S. Polyakov, (unknown), Sergey Gvozdev, M.M. Kardash, Aliaksei Bazyleuski, Andrei Yeliseyeu, Egor Lelikov, Andrei Borodko, Alexander Shneider	2025	0
20	RANDOMIZED PHASE II STUDY OF P62/SQSTM1-ENCODING PLASMID (ELENAGEN) IN COMBINATION WITH GEMCITABINE FOR PLATINUM-RESISTANT OVARIAN CANCER International Journal of Gynecological Cancer ·S. А. Krasny, Y. Baranau, Eugene Bakin, S. Polyakov, Olga Streltsova, Ekaterina Zharkova, Aliona Filimonava, Gabriel Levin, Vladimir L. Gabai, Alexander Shneider	2026	0

About S. Polyakov

S. Polyakov is a scholar working on Pulmonary and Respiratory Medicine, Surgery, Oncology, Radiology, Nuclear Medicine and Imaging and Obstetrics and Gynecology, having authored 21 papers that have together received 993 indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (7 papers), Bladder and Urothelial Cancer Treatments (5 papers), Cancer Treatment and Pharmacology (3 papers), Radiopharmaceutical Chemistry and Applications (3 papers), Cancer, Lipids, and Metabolism (2 papers), Cancer Research and Treatments (2 papers), Cancer-related Molecular Pathways (2 papers) and Endometrial and Cervical Cancer Treatments (1 paper). The work is most often cited by research in Pulmonary and Respiratory Medicine (797 citations), Cancer Research (190 citations), Radiology, Nuclear Medicine and Imaging (153 citations), Endocrinology, Diabetes and Metabolism (107 citations) and Oncology (152 citations). S. Polyakov has collaborated with scholars based in Belarus, United States and Brazil. Frequent co-authors include Mindaugas Jievaltas, Iris Kuss, Toni Sarapohja, Teuvo L.J. Tammela, Neal D. Shore, Amir Snapir, Albertas Ulys, Egils Vjaters, Murilo Luz and Karim Fizazi. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, New England Journal of Medicine, World Journal of Urology and International Journal of Gynecological Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

S. Polyakov

Impact in

Papers in i

In The Last Decade

S. Polyakov

S. Polyakov's Hit Papers

Peers

Countries citing papers authored by S. Polyakov

Fields of papers citing papers by S. Polyakov

All Works

About S. Polyakov

Explore authors with similar magnitude of impact

Papers in